Neural Analytics touts 95% accuracy for TCD platform in Expedite trial

Neural Analytics today released initial results from the Expedite study of its Transcranial Doppler Tech platform, touting 95% accuracy in the early detection of acute ischemic stroke due to large vessel occlusion.

Data from the study was presented at the 26th annual European Stroke Conference this week in Berlin.

The 45-subject trial examined the use of TCD scans in patients experiencing computer tomography angiography confirmed acute ischemic stroke due to large vessel occlusion of the internal carotid artery or middle cerebral artery.

Scans with the TCD platform were analyzed with 2 different stroke assessment algorithms, which both reported 96% accuracy for assessing large vessel occlusions.

“We are encouraged by these study results, demonstrating that under research our novel TCD platform may prove to bridge the significant gap in current stroke detection and management. Today, fewer than 10 percent of eligible stroke patients are treated surgically due to the lack of a portable diagnostic device for early detection which would enable earlier stroke diagnoses for first responders and ER physicians,” chief scientific officer Dr. Robert Hamilton said in a prepared statement.

“Current standard of care for stroke diagnosis can be expensive and time consuming, underscoring a significant unmet need for an improved method for first responders and ER physicians to rapidly and accurately assess and triage patients for appropriate clinical intervention. These results show Neural Analytics’ portable diagnostic platform has the potential to fundamentally change how we detect stroke, and could lead to significantly improved patient outcomes as patients are more rapidly triaged for treatment,” principal study investigator Dr. Thomas Devlin of Chattanooga, Tenn.’s Southeast Regional Stroke Center said in a press release.

The Los Angeles based company plans to expand the Expedite study to 140 patients, according to a press release.

In April, Neural Analytics said it raised $10.1 million in a round of equity and options financing. The company develops the Lucid M1, a portable all-in-one ultrasound system designed for rapid triaging and monitoring of patients with brain disorders.

Neural Analytic’s system is a battery operated medical grade tablet device which uses transcranial doppler to assess the brains blood vessels from outside the body. Analyses with the system can be performed in office and can help diagnose brain disorders and avoid more invasive tests, the company said.

The post Neural Analytics touts 95% accuracy for TCD platform in Expedite trial appeared first on MassDevice.

from MassDevice http://ift.tt/2rADlQP